Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ.

J Nucl Med. 2001 Apr;42(4):655-61.

2.

Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Dence CS, Ponde DE, Welch MJ, Lewis JS.

Nucl Med Biol. 2008 Aug;35(6):713-20. doi: 10.1016/j.nucmedbio.2008.06.001.

3.

Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW.

J Nucl Med. 2006 Jun;47(6):989-98.

4.

Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.

Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM.

J Nucl Med. 2013 Jul;54(7):1106-12. doi: 10.2967/jnumed.112.111120.

5.

64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2.

Li F, Jørgensen JT, Forman J, Hansen AE, Kjaer A.

J Nucl Med. 2016 Mar;57(3):437-43. doi: 10.2967/jnumed.115.155663.

PMID:
26585061
6.

Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.

Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC.

Nucl Med Biol. 2005 Aug;32(6):623-30.

PMID:
16026709
7.

Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.

Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ.

Cancer Res. 2003 Sep 1;63(17):5496-504.

8.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520.

9.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
10.

Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ.

J Nucl Med. 1999 Jan;40(1):177-83.

11.

A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.

Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82.

PMID:
11240261
12.

Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.

Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, Furukawa T, Lewis JS, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y.

Nucl Med Biol. 2003 Jul;30(5):529-34.

PMID:
12831991
13.

A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.

Hueting R, Kersemans V, Cornelissen B, Tredwell M, Hussien K, Christlieb M, Gee AD, Passchier J, Smart SC, Dilworth JR, Gouverneur V, Muschel RJ.

J Nucl Med. 2014 Jan;55(1):128-34. doi: 10.2967/jnumed.113.119917.

14.

Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.

McCall KC, Humm JL, Bartlett R, Reese M, Carlin S.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e393-9. doi: 10.1016/j.ijrobp.2012.05.005.

15.

Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning.

Myerson RJ, Singh AK, Bigott HM, Cha B, Engelbach JA, Kim J, Lamoreaux WT, Moros E, Novak P, Sharp TL, Straube W, Welch MJ, Xu M.

Int J Hyperthermia. 2006 Mar;22(2):93-115.

PMID:
16754595
16.

In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA.

Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50.

PMID:
12692685
17.

Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).

Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ, Welch MJ.

J Nucl Med. 2002 Nov;43(11):1557-69.

18.

Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.

Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, Inoue T, Kawahara N.

AJNR Am J Neuroradiol. 2013 Jan;34(1):92-9. doi: 10.3174/ajnr.A3159.

19.

Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer.

Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, Sadato N, Sugimoto K, Itoh H.

Ann Nucl Med. 2000 Oct;14(5):323-8.

PMID:
11108159
20.

A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].

Furukawa T, Yuan Q, Jin ZH, Aung W, Yoshii Y, Hasegawa S, Endo H, Inoue M, Zhang MR, Fujibayashi Y, Saga T.

Oncol Rep. 2015 Sep;34(3):1379-87. doi: 10.3892/or.2015.4079.

PMID:
26134305
Items per page

Supplemental Content

Support Center